EGFR and non-small cell lung carcinoma: Despite the above limitations, this study demonstrates that dual targeting EGFR 20ins with JMT101 and osimertinib has the potential to become a new treatment option for EGFR 20ins-positive NSCLC, especially for those with untreated baseline CNS metastases.